Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 17Nivolumab 6Docetaxel 6Gemcitabine 5Cisplatin 5Carboplatin 5durvalumab 4Paclitaxel 4Ipilimumab 4avelumab 3atezolizumab 3Filgrastim 3Cyclophosphamide 3Bortezomib 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2spartalizumab 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2abiraterone 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Nicotine 2Irinotecan 2Interleukin-2 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Drug Combinations × Head & Neck × Clear all
NCT04125693 2022-04-01

Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety

Bayer

Phase 2 Completed
1 enrolled
BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡